Noticias de NVO_US

Noticias del mercado

Últimas noticias sobre NVO_US — 135 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NVO_US ✕ 135 resultados
24/04/2026 NVO_US — Inquirer.net
‘Live Lighter’ movement debuts in PH as Novo Nordisk introduces new obesity drug, advances science-based care
24/04/2026 NVO_US — Bloomberg
General Atlantic’s Zbar Dissects a Busy Stretch for Biotech M&A
24/04/2026 NVO_US — MarketBeat
Novo Nordisk A/S (NYSE:NVO) Trading Up 5.9% - Still a Buy?
24/04/2026 NVO_US — TradingKey
Novo Nordisk A/S Stock (NVO) Moved Up by 5.67% on Apr 24: What Investors Need To Know
24/04/2026 NVO_US — Barron's
Can Eli Lilly’s Foundayo Catch Up to Novo’s Wegovy Pill?
24/04/2026 NVO_US — TradingView
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
24/04/2026 NVO_US — TechStock²
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow
24/04/2026 NVO_US — 24/7 Wall St.
JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?
24/04/2026 NVO_US — TipRanks
Why Novo Nordisk Shares Are Surging Again
24/04/2026 NVO_US — Investor's Business Daily
Battle Of The Weight-Loss Pills Continues With A Shocking Twist
24/04/2026 NVO_US — Benzinga
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
24/04/2026 NVO_US — Seeking Alpha
Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
24/04/2026 NVO_US — Bloomberg
Lilly’s New Obesity Pill Off to Slow Start in Race With Novo
23/04/2026 NVO_US — Yahoo Finance
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
23/04/2026 NVO_US — Yahoo Finance
Novo Nordisk Expands GLP-1 Reach With Pediatric Oral Semaglutide Data
23/04/2026 NVO_US — Reuters
Novo Nordisk's diabetes pill cuts blood sugar in key trial in children
23/04/2026 NVO_US — Benzinga
What's Going On With Novo Nordisk Stock Thursday? - Novo Nordisk (NYSE:NVO)
23/04/2026 NVO_US — Fierce Pharma ES ← EN
Tras ganar el ensayo, Novo Nordisk contempla la aprobación de semaglutida oral para pacientes con diabetes en adolescentes
23/04/2026 NVO_US — The Motley Fool
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
23/04/2026 NVO_US — The Pharma Letter ES ← EN
La semaglutida oral de Novo Nordisk muestra un gran potencial para los niños con diabetes tipo 2

Página 1 de 7

keyboard_arrow_up